🧾 What This Document Is

This is a Post-Effective Amendment to a registration statement. Think of it as a mandatory update to a previously approved document. Silo Pharma is refreshing its paperwork with the SEC to include its 2025 financial statements and to keep the registration alive. This specific update allows certain investors (the "Selling Shareholders") to potentially resell up to 820,911 shares of common stock that they could get by exercising warrants they own. The company itself isn't selling new shares here; it's just facilitating a potential resale market for existing warrant holders.

👉 Key Takeaway: This is procedural paperwork that keeps a door open for some early investors to sell their stock if they choose to exercise their warrants.

🏢 What The Company Does (And What It's Becoming)

Silo Pharma, Inc. is a developmental-stage biopharmaceutical company. In simple terms, it's a drug development startup focused on creating treatments for conditions like PTSD, anxiety, fibromyalgia, and central nervous system diseases. However, the filing reveals a massive strategic pivot. The company is now heavily involved in a "digital asset treasury strategy," meaning it holds and manages significant investments in cryptocurrencies like Bitcoin (BTC), Ethereum (ETH), and Solana as a core part of its business operations.

👉 Why It Matters: This isn't just a biotech company anymore. It's becoming a hybrid entity with a major focus on cryptocurrency, which introduces a whole new set of risks and a different business model than its original drug development path.

🚀 The Warrant Resale Mechanics

The filing details the specifics of whose warrants are being registered for resale:

• Investor Warrants: These allow the purchase of 763,638 shares at $2.75 per share.
• Placement Agent Warrants: These allow the purchase of 57,273 shares at $3.4375 per share.
• The Bottom Line: If all these warrants are exercised with cash, Silo Pharma could receive up to ~$2.3 million in total proceeds. This cash would be used for working capital, development, and general corporate purposes. However, there's no guarantee the warrants will ever be exercised.

⚖️ Major Risks: The Nasdaq Delisting Threat

A critical operational risk is highlighted: On July 3, 2025, Nasdaq notified Silo Pharma that its stock price was too low (below the required $1.00 minimum bid price). The company was given until December 24, 2025, to fix it, and then was granted an extension until June 22, 2026. If it doesn't get its stock price back above $1.00 by then, it faces being delisted from the Nasdaq Capital Market. Delisting would make the stock harder to trade, likely reduce its price, and harm the company's ability to raise money.

👉 Why It Matters: This is a ticking clock. Maintaining a major stock exchange listing is crucial for investor confidence and liquidity. Failure would be a serious blow.

📦 Financial Position & Capital Structure

As of April 10, 2026, there were 16,266,593 shares of common stock outstanding. The filing also lists a large number of other warrants and options that could be converted into more shares in the future, potentially diluting the ownership percentage of current shareholders. The company's stock closed at $0.4160 on April 9, 2026, well below the Nasdaq requirement.

👉 Why It Matters: The company has a complex capital structure with many potential shares that could be created. This "overhang" can put downward pressure on the stock price because investors anticipate future dilution.

🔮 Strategic Pivot & Digital Asset Risks

The most significant revelation is Silo Pharma's shift to holding digital assets. This strategy comes with massive, unique risks that dominate the "Risk Factors" section:

• Extreme Volatility: The value of crypto holdings can swing wildly.
• Regulatory Uncertainty: Governments worldwide are still creating rules for crypto, which could negatively impact the company.
• Competitive Risk: It now competes with other firms and spot ETFs for crypto investment.
• Technological Risk: Issues like blockchain "forks" or security breaches could lead to losses.
• Operational Risk: The company has "limited history" with this strategy. It's a new, unproven business line for a former biotech firm.

👉 Why It Matters: Investors are no longer just betting on drug trials. They are now exposed to the highly speculative and volatile cryptocurrency market through this company's treasury strategy.

🧠 The Analogy

Silo Pharma is like a former chef who has opened a gold trading desk in the back of their restaurant. The original business (drug development) is still there, but management's attention and a large portion of the company's capital are now focused on a completely different, high-risk activity (trading crypto). The restaurant's customers (stock investors) have to decide if they're okay with this major shift in business, the new risks involved, and whether the chef is an expert in both fields.

🧩 Final Takeaway

This filing shows a biotech company in the middle of a radical transformation. While it performs the routine task of updating a registration for warrant holders, its core message is that Silo Pharma is now a dual-risk company: it carries the inherent risks of drug development plus the severe volatility and regulatory risks of a cryptocurrency treasury strategy, all while fighting to keep its stock price above the Nasdaq delisting threshold.